Athersys Reports Results of Multistem Cell Therapy (IV) in Patients with Acute Respiratory Distress Syndrome (ARDS)
Shots:
- The study involves assessing multistem therapy (IV)(n=20) vs PBO (n=10) in patients with ARDS for 28 days
- Study results: Lower mortality (LM)(25% vs 40%); VF days (12.9 vs 9.2); ICU-free days (10.3 vs 8.1); In severe ARDS: LM (25% vs 50%); ventilator-free (VF)@ days (14.6 vs 8.0); ICU-free @days (11.4 vs 5.9) and was well tolerated
- Multistem Cell Therapy (IV) is a regenerative product- targeted for tissue repairing including healing for multiple therapeutic areas. Athersys is also conducting P-III MASTER-2 study for patients with ischemic stroke and acute MI
Ref: Globe Newswire | Image: Youtube
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com